StemCells Inc (STEM.OQ) Company Profile | Reuters.com
Edition:
United States

Profile: StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

0.39USD
24 Jun 2016
Change (% chg)

$-0.04 (-8.33%)
Prev Close
$0.43
Open
$0.33
Day's High
$0.41
Day's Low
$0.33
Volume
166,021
Avg. Vol
75,722
52-wk High
$8.88
52-wk Low
$0.33

StemCells, Inc. (StemCells), incorporated on August 2, 1988, is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company's lead product development program is its central nervous system (CNS) Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system, which consists of the brain, spinal cord and eye.

The Company has completed Phase I clinical trial for Pelizeaus-Merzbacher Disease. It has also completed the Phase I clinical trial for Neuronal Ceroid Lipofuscinosis (also known as Batten disease). It has completed the Phase I/II clinical trial in multiple sites for chronic spinal cord injury. The Company is conducting Pathway Study, a Phase II proof-of-concept clinical trial using its HuCNS-SC cells for the treatment of cervical spinal cord injury (SCI).

The Company is conducting a Phase I/II clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC cells as a treatment for dry age-related macular degeneration (AMD). It has conducted a Radiant Study, which is a Phase II randomized, controlled proof-of-concept study, designed to evaluate both the safety and efficacy of its HuCNS-SC cells for the treatment of geographic atrophy (GA).

Company Address

StemCells Inc

3155 PORTER DRIVE
PALO ALTO   CA   94304
P: +1650.4753100
F: +1510.4564001

Company Web Links